Published in final edited form as:

Hepatology. 2013 April ; 57(4): 1357–1365. doi:10.1002/hep.26156.

Association between Non-invasive Fibrosis Markers and Mortality among Adults with Non-alcoholic Fatty Liver Disease in the United States

Donghee Kim^{1,2}, W. Ray Kim¹, Hwa Jung Kim³, and Terry M. Therneau⁴

Donghee Kim: messmd@chol.com; Hwa Jung Kim: rsvp@amc.seoul.kr; Terry M. Therneau: therneau@mayo.edu

¹Division of Gastroenterology and Hepatology, Mayo Clinic College of Medicine, Rochester, MN, USA

²Department of Internal Medicine, Healthcare Research Institute, Seoul National University Hospital Healthcare System Gangnam Center, Seoul, Korea

³Department of Clinical Epidemiology and Biostatistics, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea

⁴Division of Biomedical Statistics and Informatics, Mayo Clinic College of Medicine, Rochester, MN, USA

Abstract

The clinical and public health significance of non-alcoholic fatty liver disease (NAFLD) is not well established. We investigate the long-term impact of NAFLD on mortality. This analysis utilizes the National Health and Nutrition Examination Survey conducted in 1988–1994 and subsequent follow-up data for mortality through December 31, 2006. NAFLD was defined by ultrasonographic detection of hepatic steatosis in the absence of other known liver diseases. The presence and severity of hepatic fibrosis in subjects with NAFLD was determined by the NAFLD fibrosis score (NFS), the AST-platelet ratio index (APRI), and the FIB-4 score. Out of 11,154 participants, 34.0% had NAFLD - the majority (71.7%) had NFS consistent with lack of significant fibrosis ($NFS < -1.455$), whereas 3.2% had a score indicative of advanced fibrosis ($NFS > 0.676$). After a median follow-up of 14.5 years, NAFLD was not associated with higher mortality (age- and sex-adjusted hazard ratio (HR) 1.05, 95% confidence interval (CI) 0.93–1.19). In contrast, there was a progressive increase in mortality with advancing fibrosis scores. Compared to subjects without fibrosis, those with a high probability of advanced fibrosis had a 69% increase in mortality (HR 1.69 (95% CI 1.09–2.63) for NFS, 1.85 (1.02–3.37) for APRI, 1.66 (0.98–2.82) for FIB-4) after adjustment for other known predictors of mortality. These increases in mortality were almost entirely from cardiovascular causes (HR 3.46 (95% CI 1.91–6.25) for NFS, 2.53 (1.33–4.83) for APRI, 2.68 (1.44–4.99) for FIB-4).

Correspondence: W. Ray Kim, MD, Telephone: 507-538-1149, Fax: 507-538-3974. kim.ray@mayo.edu.

Disclosures

No conflict to disclose

Author contributions

Dr. Donghee Kim was involved in study concept and design, acquisition of data, analysis and interpretation of data, drafting of the manuscript; Dr. W. Ray Kim was involved in study concept and design, analysis and interpretation of data, drafting of the manuscript, critical revision of the manuscript for important intellectual content, and study supervision; Dr. Hwa Jung Kim was involved in acquisition of data, statistical analysis and interpretation of data, and critical revision of the manuscript for important intellectual content; Dr. Terry M. Therneau was involved in statistical analysis and interpretation of data, and critical revision of the manuscript for important intellectual content.

Conclusions—Ultrasonography-diagnosed NAFLD is not associated with increased mortality. However, advanced fibrosis as determined by non-invasive fibrosis marker panels is a significant predictor of mortality, mainly from cardiovascular causes, independent of other known factors.

Keywords

Hepatic steatosis; Fatty liver; National Health and Nutrition Examination Survey; Survival; Mortality

In the past 25 years, the prevalence of obesity in the US has more than doubled, a trend that continues today without signs of slowing down.(1, 2) In parallel, non-alcoholic fatty liver disease (NAFLD) has been recognized as the most prevalent liver disease in the US and in many parts of the world.(2, 3) The natural history of NAFLD, however, is incompletely understood and its clinical and public health significance remains a matter of debate.

NAFLD is a clinicopathological entity that encompasses simple steatosis without fibrosis, non-alcoholic steatohepatitis (NASH) with varying stages of fibrosis, and cirrhosis. Patients with simple steatosis are thought to have benign prognosis (4), whereas those with NASH may develop progressive liver disease.(5–7) One of the challenges in studying NAFLD in large groups of individuals is that the strict, traditional definition of NAFLD and NASH requires a liver biopsy, which makes it difficult to implement a population-based study.(8) Further, characteristic features of NASH such as steatosis, inflammation, and ballooning of hepatocytes may diminish as fibrosis advances.(9, 10)

While a consensus is lacking as to optimal surrogate indicators for NAFLD and NASH for large scale, population-based, epidemiological studies, a number of non-invasive tools may be considered. First, for the diagnosis of steatosis, abdominal ultrasound has been shown to have a sufficient degree of diagnostic accuracy.(11) Second, methods to non-invasively diagnose hepatic fibrosis have been developed; they include serum marker panels and mechanical measures of liver stiffness, both of which have been correlated with hepatic fibrosis. Of those, the NAFLD fibrosis score (NFS) and FIB-4 score are scoring systems designed to identify or exclude advanced fibrosis in patients with a diagnosis of NAFLD. (12–14) In addition, the Aspartate transaminase to Platelet Ratio Index (APRI), originally created for chronic hepatitis C, is another simple marker that has been used for patients with NAFLD. (15, 16)

In this study, we take advantage of the National Health and Nutrition Examination Survey (NHANES) data to determine the mortality impact of NAFLD and advanced fibrosis in NAFLD. NAFLD is defined by the ultrasonographic appearance of the liver, whereas NFS, APRI, and FIB-4 score were used to detect NAFLD with a discernible degree of fibrosis. Thus, the aim of our study was to investigate the effect of NAFLD in general and that of NAFLD with fibrosis on overall and cause-specific mortality in the US adult population.

METHODS

Subjects and study design

This study represents an analysis of the third NHANES data (1988–1994, the National Center for Health Statistics, the Center for Disease Control and Prevention) including the follow-up mortality data (NHANES III-Linked Mortality Files). NHANES employs a stratified, multi-stage, clustered probability sampling design to reach a representative sample of the non-institutionalized civilian population in the US.

14,797 adult (20–74 years) participants of the NHANES III survey examined laboratory tests at mobile examination center (Figure 1). Of those, subjects with excessive alcohol consumption (>21 drinks/week in men and >14 drinks/week in women)(17), viral hepatitis (positive serum hepatitis B surface antigen, positive serum hepatitis C antibody), iron overload (transferrin saturation ≥ 50%), or pregnant women were excluded.(n=1,621) Out of the remaining 13,176 participants, hepatic steatosis could be evaluated in 12,317 (93.5%). We removed subjects in whom data on serum aminotransferase, alcohol consumption, or body mass index, waist circumference, albumin, or platelet count were missing. Thus, the final study sample consisted of 11,154 adults with complete data. The original survey was approved by the Centers for Disease Control and Prevention's Institutional Review Board, and all participants provided written informed consent to participate. This analysis per se was deemed exempt by the Institutional Review Board of the Mayo Foundation, as the data set used in the analysis was completely de-identified.

Clinical and Laboratory Evaluation

A wide array of demographic, lifestyle and dietary information as well as anthropometric assessment and comprehensive laboratory data were available in the data set. Hypertension was defined as systolic blood pressure ≥ 140 mmHg or diastolic blood pressure ≥ 90 mmHg and/or previous use of antihypertensive medication. Diabetes mellitus was diagnosed in subjects with history of diabetes diagnosis and/or treatment with a hypoglycemic agent or insulin. Insulin resistance was defined by the top quartile of the homeostasis model assessment of insulin resistance (HOMA-IR, fasting glucose x fasting insulin/22.5) among subjects without diabetes in each gender. Current smokers were subjects who reported ongoing smoking or those who had smoked at least 100 cigarettes in the preceding 5 years. History of cardiovascular disease was defined as self-reported history of congestive heart failure, stroke, or myocardial infarction.

NAFLD and Advanced Fibrosis

The original NHANES III examination included ultrasonography of the gallbladder at a mobile examination center as a part of the assessment for digestive diseases in adults aged 20 to 74 years. Subsequently, the archived gallbladder ultrasound video images were reviewed to assess fatty liver.(18) Three ultrasound reviewers were trained by a board certified radiologist who specialized in hepatic imaging. Evaluation of the fatty liver was performed using the following five criteria: 1) parenchymal brightness, 2) liver to kidney contrast, 3) deep beam attenuation, 4) bright vessel walls, and 5) gallbladder wall definition. The overall assessment, made using an algorithm based on these five criteria, reported normal versus mild, moderate, or severe hepatic steatosis.(18) For the purpose of this study, NAFLD was diagnosed in subjects with any degree (mild to severe) of steatosis.

In individuals with NAFLD, serum markers of fibrosis were used to assess severity of fibrosis. These included NFS, APRI and FIB-4. NFS was calculated according to the published formula:

$$\text{NFS} = -1.675 + 0.037 \times \text{age (years)} + 0.094 \times \text{BMI (kg/m}^2\text{)} + 1.13 \times \text{impaired fasting glycemia or diabetes (yes=1, no=0)} + 0.99 \times \text{AST/ALT ratio} - 0.013 \times \text{platelet (}\times 10^9\text{/L)} - 0.66 \times \text{albumin g/dL}.$$

(12) Two cutoff points were selected to categorize subjects with NAFLD into three groups, including those with high probability (NFS>0.676), intermediate probability (NFS: 0.676~–1.455) and low probability for advanced fibrosis (NFS<–1.455).(12) APRI was also calculated by the published formula:

$$\text{APRI} = ([\text{AST}/\text{upper limit of normal}]/\text{platelet count} [10^9/\text{L}]) \times 100.$$

(15) We used the cut-offs for low and high probability of advanced fibrosis as published, namely 0.5 and 1.5, respectively. (15) FIB-4 was calculated by the following formula:

$$\text{FIB-4} = (\text{Age} [\text{years}] \times \text{AST} [\text{U/L}]) / (\text{platelet} [10^9/\text{L}] \times (\text{ALT} [\text{U/L}])^{1/2}).$$

Published cut-off values were used to define low (FIB-4 < 1.30), intermediate and high (FIB-4 > 2.67) probability of advanced fibrosis. (19)

Mortality

All participants of NHANES III over 17 years of age were followed forward for mortality through December 31, 2006. The NHANES III-Linked Mortality File uses the Underlying Cause of Death 113 (UCOD_113) code to classify all deaths according to the International Classification of Diseases, 9th Revision (ICD-9) for deaths prior to 1998 and to ICD-10 for those between 1999 and 2006. (20) Overall mortality and the following four cause-specific mortality was assessed: (1) cardiovascular (UCOD_113 55–63, 67–74) including ischemic heart disease, heart failure, atherosclerosis, cerebrovascular disease, aortic aneurysm and other diseases of arteries; (2) malignancy (UCOD_113 20–23, 25–36, 43) including all malignant neoplasms of solid organs; (3) liver-related (UCOD_113 15, 24, 93–95) including chronic liver diseases, cirrhosis, and hepatocellular carcinoma; and (4) diabetic complications (E10–14). (20)

Statistical analysis

The main tool for data analysis was the SAS callable SUDAAN 10.0.1 (Research Triangle Institute, Research Triangle Park, NC, USA), which allows appropriate use of the stratified sampling scheme employed by NHANES to project the data to the U.S. population. (21)

We analyzed frequencies of categorical variables and means $\pm$ SE of continuous variables (PROC CROSSTAB, PROC DESCRIPT). Baseline characteristics across groups were compared using the chi-square test for categorical variables and the two sample *t* test or ANOVA for continuous variables (PROC CROSSTAB, PROC REGRESS). Survival analysis including overall and cause-specific mortality utilized the Cox proportional hazards regression analysis (PROC SURVIVAL).

RESULTS

NAFLD and Its Impact on Survival

The prevalence of NAFLD (mild to severe steatosis by ultrasonography) among the eligible subjects was 34.0%, which projected to a minimum of 43.2 million American adults. If the definition of NAFLD is restricted to moderate to severe steatosis, 20.2% were affected, corresponding to 25.6 million individuals. The demographic and clinical characteristics of subjects with NAFLD are summarized in Table 1 and are consistent with what is known of patients with NAFLD. For example, subjects with NAFLD were more likely to be older, male, hypertensive and diabetic than those without steatosis. Similarly, body mass index, waist circumference, plasma concentrations of total cholesterol and fasting glucose, and HOMA index were greater in NAFLD subjects.

The median follow-up in the 11,154 participants was 14.5 years (range, 0.03–18.1 years). There were a total of 1,795 deaths during the follow-up (15-year Kaplan-Meier survival: 83.7%). The most common cause of death was cardiovascular (9.3%) and malignancy (5.0%). Liver disease accounted for 0.4% of deaths. The 15-year unadjusted Kaplan-Meier survival in NAFLD subjects was 80.6% compared to 85.5% in those without NAFLD. Table 2 summarizes results of the Cox-regression analysis. After adjustment for age and sex, subjects with NAFLD had slightly and non-significantly higher overall mortality than those without NAFLD (hazard ratio [HR] 1.05; 95% confidence interval [CI] 0.93–1.19, $p=0.431$). When additional demographic and clinical covariates such as race/ethnicity, diabetes, and hypertension were taken into account, NAFLD had no association with mortality from all causes (HR 0.89; 95% CI 0.78–1.02). Similarly, NAFLD had no impact on cause-specific mortality. There were 37 deaths from liver-related causes, 19 of which occurred among NAFLD subjects. This gave rise to a fully adjusted HR for liver-related death of 1.90 with a wide confidence interval, as expected from the small number of events. When the analysis was repeated with the definition of NAFLD restricted to moderate-severe steatosis, NAFLD had no demonstrable effect on mortality (data not shown).

NAFLD with Fibrosis and Survival

Out of the subjects with NAFLD, 28.3% had NFS consistent with an intermediate (25.1%) to high (3.2%) probability of fibrosis, while the remainder (71.7%) had a low probability. These data project to 10.8 million American adults with NAFLD and some evidence of advanced fibrosis, including 1.4 million with a high probability and another 9.4 million with an intermediate probability.

Table 3 compares those three groups of subjects with NAFLD using NFS. As expected from the component variables of the score, advanced fibrosis was associated with older age. There was a larger proportion of Non-Hispanic blacks and smaller portion of Mexican Americans among those with a high probability of advanced fibrosis. For most clinical parameters, increasing NFS was associated with more severe metabolic syndrome, such as body mass index, waist circumference, prevalence of hypertension and diabetes, and the HOMA index. When APRI and FIB-4 were used for similar comparisons (data not shown), the clinical and metabolic parameters of subjects with low to intermediate to high probabilities of advanced fibrosis were similar to the data presented in Table 3.

In Table 4, among NAFLD subjects, increasing NFS was associated with progressively higher risk of mortality – patients with a high probability of advanced fibrosis had a 69% increase in overall mortality (hazard ratio [HR] 1.69, 95% confidence interval [CI] 1.09–2.63, after full adjustment) compared to the low probability group, whereas those with intermediate score had 26% increase in mortality (HR 1.26, 95% CI 0.98–1.64, after full adjustment). In cause-specific mortality analyses, the increase in mortality associated with fibrosis was essentially driven by cardiovascular causes. For example, subjects with a high NFS had 3.46 fold (95% CI 1.91–6.25, after full adjustment) increase in cardiovascular mortality compared to those with low NFS. Again, the number of liver-related death ($n=19$) was too small to discern any trends.

When the analysis was repeated using APRI as a marker of fibrosis, the results were overall identical to those obtained using NFS. In Table 5, for overall mortality, APRI increased the risk of mortality significantly with a multivariable hazard ratio of 1.85 (95% CI 1.02–3.37) for high probability of advanced fibrosis. Similarly, high APRI was associated with cardiovascular disease (HR 2.53 95% CI 1.33–4.83). These results were essentially the same, when FIB-4 was used (Table 5). We conducted an additional sensitivity analysis by including HOMA-IR in the model, which did not change the results (data not shown). In

another sensitivity analysis, cases with moderate to severe steatosis were compared to those with mild or no steatosis, which did not alter the results (data not shown).

DISCUSSION

The main findings in this large, prospective, nationally representative, population-based study include (1) NAFLD, as detected by ultrasonography, in and of itself did not increase the risk of mortality, whereas (2) NAFLD with evidence of advanced fibrosis, defined in this study by non-invasive marker panels, was associated with increased mortality. Further, the increase in mortality was mainly attributable to cardiovascular causes.

NAFLD is common - a recent systemic review estimated the prevalence of NAFLD to be 10% to 35% and that of NASH between 3% and 5% in the general population.(22) Despite its prevalence, the natural history of NAFLD is yet to be fully defined. It is understood that among individuals with NAFLD, simple steatosis is a benign condition, whereas NASH can progress to fibrosis, cirrhosis and hepatocellular carcinoma. However, the prevalence of NASH and the incidence of sequelae of chronic liver disease in individuals with NAFLD in the population at large are difficult to obtain. Traditional histologic definitions of NASH, such as hepatocellular necroinflammation and ballooning are poorly suited for epidemiological studies (23), as it would be impractical, if not unethical, to obtain liver biopsies in asymptomatic community residents for a research purpose.

Given these limitations, previous investigators have used serum ALT activities and/or radiographic means to define NAFLD and distinguish between simple steatosis and NASH with and without fibrosis. To date, three manuscripts have been published in which serum ALT data were used as a surrogate indicator of NAFLD in the NHANES III and NHANES III-Linked Mortality Files.(24–26) Although they were slightly different from one another in the study design, disparate conclusions were reached. One study found that ALT elevation was associated with an 8-fold increase in liver-related mortality but not with overall mortality (24), whereas another reported that increase in mortality was restricted to certain age groups only.(25) Serum ALT is a suboptimal indicator for NAFLD because it is neither sensitive nor specific for NAFLD. For example, a well-publicized population-based study observed that as many as 79% of subjects with hepatic steatosis determined by magnetic resonance spectroscopy had serum ALT within normal limits.(27) Obviously, serum ALT is entirely non-specific for NAFLD and the accuracy of ALT in the detection of NAFLD depends on the degree to which other etiologies of liver disease can be confidently excluded. Further, as serum ALT often decreases as fibrosis progresses in NAFLD patients, an important subgroup of NAFLD patients, namely those with advanced fibrosis, may be systemically under-represented if ALT alone is used for detection of NAFLD.

To the extent that abdominal ultrasonography is widely used in clinical practice, detection of steatosis is one of the most commonly encountered scenarios in which NAFLD is suspected and diagnosed. While ultrasonography may not be as accurate as magnetic resonance spectroscopy, its utility in the diagnosis of hepatic steatosis is quite high as shown in a recent systemic review.(11) The main limitation of ultrasonography in the evaluation of patients with NAFLD is that it is unable to distinguish between NAFLD with and without advanced fibrosis, unless there are gross morphological changes consistent with cirrhosis. Since the ultrasonographic description of hepatic steatosis has been released for the NHANES participants, a recent analysis of the NHANES data attempted to better define NASH by the combination of ultrasonography and serum ALT activities.(28) Using those definitions, the investigators found neither NAFLD nor NASH had any impact on subsequent mortality. The main limitation of the study was the use of serum ALT in defining NASH, which, as discussed above, is a suboptimal surrogate.

Using the same data set but employing a more specific diagnostic marker for fibrosis, namely the NFS, APRI and FIB-4, we came to a slightly different conclusion –that is NAFLD associated with evidence of fibrosis has a significant impact on subsequent mortality. It is noteworthy that most of the increase in mortality was due to cardiovascular causes, even when typical risk factors for atherosclerotic disease such as hypertension, diabetes, tobacco smoking, history of cardiovascular disease, and lipid disorders were already taken into account. This observation is consistent with prior data that NAFLD is an independent predictor of cardiovascular morbidity.(29–31)

With regard to mortality from liver disease, the lack of significant association between NAFLD with or without fibrosis and mortality in this study should not be construed as a proof that NAFLD does not lead to morbidity and mortality from chronic liver disease. Instead, we believe that it is likely a type II error that, despite the large sample size of the NHANES study, the number of deaths from liver disease in the data set was too low to draw a firm conclusion. In addition, in patients with NAFLD, cardiovascular disease represents such a strong competing risk that the study of the impact of NAFLD on liver-related mortality may require a much larger sample and/or longer follow-up. In the mean time, it may be fair to point out that, the absolute risk of liver mortality in subjects with NAFLD in the general population is quite small. This is in contrast to prior investigations, frequently conducted in NAFLD patients who underwent liver biopsies at specialty liver clinics, which showed increased mortality from liver disease.(5–7, 32) The difference between those and population-based studies such as ours is probably attributable to selection bias entailed in referral patients. Based on our data, we believe that, although it is wise to follow NAFLD patients with advanced fibrosis from the liver standpoint, it may be more important to pay attention to their cardiovascular risk in order to improve their overall outcome.

We do acknowledge limitations of this study. With regard to the assessment for steatosis and fibrosis, neither ultrasonography nor the fibrosis markers used in the study is an ideal diagnostic modality in an individual patient. For population-based epidemiological studies like this, a balance needs to be sought between the accuracy of the diagnostic tools and feasibility of obtaining the diagnostic information. With regard to NFS, although it was originally developed in narrowly defined patient populations, it has subsequently been validated in heterogeneous groups of NAFLD patients as a correlate of liver histology, as shown in a recent meta-analysis, which incorporated 13 studies covering 3,064 patients of different ethnicities, ages, obesity, and diabetes status.(12, 33–35)

While its use is advocated by the practice guidelines (17), for the purpose of this study, NFS has the limitation of including variables such as age and diabetes, which in and of themselves correlate with survival. Thus, a potential criticism is that the association between high NFS and mortality is confounded by those variables and not necessarily indicative of the effect of fibrosis. This consideration highlights the necessity and importance of multivariable analyses that incorporate appropriate adjustment for those and other relevant variables. In addition, replication of the same results in analyses based on APRI and FIB-4 adds to the confidence that the results are reproducible. Another potential concern for our data is the relatively large proportion (15.3%) of attrition of study subjects from the eligible NHANES III sample to the final analysis data set. A large part of this reduction was due to lack of ultrasonographic data and missing data of important variables. Availability of ultrasonographic data has been reported to be random and comparisons between the larger NHANES sample and that with complete data showed similar demographic characteristics. (36, 37)

With these caveats in mind, we offer the following conclusions. First, as previously reported, NAFLD is highly prevalent among US adults. Clearly, the prevalence of NAFLD

is extremely high, which translates to a large aggregate disease burden, be it cardiovascular-, diabetes-, or liver-related. Second, from this and other studies, it is clear that NAFLD without advanced fibrosis has little impact on mortality upon follow-up up to two decades. (4, 6, 7, 38) However, NAFLD with advanced fibrosis is an independent predictor of increased mortality, mainly from cardiovascular causes. In those patients, rigorous interventions to modify cardiovascular risk factors as well as careful follow-up for progression of fibrosis may be warranted.

Acknowledgments

Financial support

This work was supported in part by a grant from the National Institute of Diabetes, Digestive and Kidney Disease (DK-34238) and by the GlaxoSmithKline Research Fund of the Korean Association for the Study of the Liver. The funding organizations played no role in the design and conduct of the study, in the collection, management, analysis, and interpretation of data, or in the preparation, review, or approval of the manuscript.

List of Abbreviations

ALT	alanine aminotransferase
APRI	aspartate transaminase to platelet ratio index
CI s	confidence intervals
HR	hazard ratio
NAFLD	non-alcoholic fatty liver disease
NASH	nonalcoholic steatohepatitis
NFS	NAFLD fibrosis score
NHANES	National Health and Nutrition Examination Survey

References

1. Klein S. The national obesity crisis: a call for action. *Gastroenterology*. 2004; 126:6. [PubMed: 14699480]
2. Lim YS, Kim WR. The global impact of hepatic fibrosis and end-stage liver disease. *Clin Liver Dis*. 2008; 12:733–746. [PubMed: 18984463]
3. Ong JP, Younossi ZM. Epidemiology and natural history of NAFLD and NASH. *Clin Liver Dis*. 2007; 11:1–16. [PubMed: 17544968]
4. Dam-Larsen S, Franzmann M, Andersen IB, Christoffersen P, Jensen LB, Sorensen TI, Becker U, et al. Long term prognosis of fatty liver: risk of chronic liver disease and death. *Gut*. 2004; 53:750–755. [PubMed: 15082596]
5. Ekstedt M, Franzen LE, Mathiesen UL, Thorelius L, Holmqvist M, Bodemar G, Kechagias S. Long-term follow-up of patients with NAFLD and elevated liver enzymes. *Hepatology*. 2006; 44:865–873. [PubMed: 17006923]
6. Rafiq N, Bai C, Fang Y, Srishord M, McCullough A, Gramlich T, Younossi ZM. Long-term follow-up of patients with nonalcoholic fatty liver. *Clin Gastroenterol Hepatol*. 2009; 7:234–238. [PubMed: 19049831]
7. Soderberg C, Stal P, Askling J, Glaumann H, Lindberg G, Marmur J, Hultcrantz R. Decreased survival of subjects with elevated liver function tests during a 28-year follow-up. *Hepatology*. 2010; 51:595–602. [PubMed: 20014114]
8. Angulo P. Long-term mortality in nonalcoholic fatty liver disease: is liver histology of any prognostic significance? *Hepatology*. 2010; 51:373–375. [PubMed: 20101746]

9. Adams LA, Sanderson S, Lindor KD, Angulo P. The histological course of nonalcoholic fatty liver disease: a longitudinal study of 103 patients with sequential liver biopsies. *J Hepatol.* 2005; 42:132–138. [PubMed: 15629518]
10. Angulo P. GI epidemiology: nonalcoholic fatty liver disease. *Aliment Pharmacol Ther.* 2007; 25:883–889. [PubMed: 17402991]
11. Hernaez R, Lazo M, Bonekamp S, Kamel I, Brancati FL, Guallar E, Clark JM. Diagnostic accuracy and reliability of ultrasonography for the detection of fatty liver: a meta-analysis. *Hepatology.* 2011; 54:1082–1090. [PubMed: 21618575]
12. Angulo P, Hui JM, Marchesini G, Bugianesi E, George J, Farrell GC, Enders F, et al. The NAFLD fibrosis score: a noninvasive system that identifies liver fibrosis in patients with NAFLD. *Hepatology.* 2007; 45:846–854. [PubMed: 17393509]
13. Vallet-Pichard A, Mallet V, Nalpas B, Verkarre V, Nalpas A, Dhalluin-Venier V, Fontaine H, et al. FIB-4: an inexpensive and accurate marker of fibrosis in HCV infection. comparison with liver biopsy and fibrotest. *Hepatology.* 2007; 46:32–36. [PubMed: 17567829]
14. Sterling RK, Lissen E, Clumeck N, Sola R, Correa MC, Montaner J, MSS, et al. Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection. *Hepatology.* 2006; 43:1317–1325. [PubMed: 16729309]
15. Wai CT, Greenon JK, Fontana RJ, Kalbfleisch JD, Marrero JA, Conjeevaram HS, Lok AS. A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C. *Hepatology.* 2003; 38:518–526. [PubMed: 12883497]
16. Cales P, Laine F, Boursier J, Deugnier Y, Moal V, Oberti F, Hunault G, et al. Comparison of blood tests for liver fibrosis specific or not to NAFLD. *J Hepatol.* 2009; 50:165–173. [PubMed: 18977552]
17. Chalasani N, Younossi Z, Lavine JE, Diehl AM, Brunt EM, Cusi K, Charlton M, et al. The diagnosis and management of non-alcoholic fatty liver disease: practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association. *Hepatology.* 2012; 55:2005–2023. [PubMed: 22488764]
18. NCHS. NHANES III Hepatic Steatosis Ultrasound Images Assessment Procedures Manual. Available from: http://www.cdc.gov/nchs/data/nhanes/nhanes3/Hepatic_Steatosis_Ultrasound_Procedures_Manual.pdf
19. Shah AG, Lydecker A, Murray K, Tetri BN, Contos MJ, Sanyal AJ. Nash Clinical Research N. Comparison of noninvasive markers of fibrosis in patients with nonalcoholic fatty liver disease. *Clin Gastroenterol Hepatol.* 2009; 7:1104–1112. [PubMed: 19523535]
20. NCHS. NHANES III File Layout and Detailed Notes for Selected Variables. Available from: http://www.cdc.gov/nchs/data/datalinkage/nh3_file_layout_public_2010.pdf
21. National Center for Health Statistics. Plan and operation of the NHANES III, 1988–94. *Vital health stat.* 1994;1–407.
22. Vernon G, Baranova A, Younossi ZM. Systematic review: the epidemiology and natural history of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in adults. *Aliment Pharmacol Ther.* 2011; 34:274–285. [PubMed: 21623852]
23. Kleiner DE, Brunt EM, Van Natta M, Behling C, Contos MJ, Cummings OW, Ferrell LD, et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. *Hepatology.* 2005; 41:1313–1321. [PubMed: 15915461]
24. Ruhl CE, Everhart JE. Elevated serum alanine aminotransferase and gamma-glutamyltransferase and mortality in the United States population. *Gastroenterology.* 2009; 136:477–485. e411. [PubMed: 19100265]
25. Dunn W, Xu R, Wingard DL, Rogers C, Angulo P, Younossi ZM, Schwimmer JB. Suspected nonalcoholic fatty liver disease and mortality risk in a population-based cohort study. *Am J Gastroenterol.* 2008; 103:2263–2271. [PubMed: 18684196]
26. Ong JP, Pitts A, Younossi ZM. Increased overall mortality and liver-related mortality in non-alcoholic fatty liver disease. *J Hepatol.* 2008; 49:608–612. [PubMed: 18682312]

27. Browning JD, Szczepaniak LS, Dobbins R, Nuremberg P, Horton JD, Cohen JC, Grundy SM, et al. Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity. *Hepatology*. 2004; 40:1387–1395. [PubMed: 15565570]
28. Lazo M, Hernaez R, Bonekamp S, Kamel IR, Brancati FL, Guallar E, Clark JM. Non-alcoholic fatty liver disease and mortality among US adults: prospective cohort study. *BMJ*. 2011; 343:d6891. [PubMed: 22102439]
29. Targher G, Day CP, Bonora E. Risk of cardiovascular disease in patients with nonalcoholic fatty liver disease. *N Engl J Med*. 2010; 363:1341–1350. [PubMed: 20879883]
30. Choi SY, Kim D, Kim HJ, Kang JH, Chung SJ, Park MJ, Kim YS, et al. The relation between non-alcoholic fatty liver disease and the risk of coronary heart disease in Koreans. *Am J Gastroenterol*. 2009; 104:1953–1960. [PubMed: 19491838]
31. Kim D, Choi SY, Park EH, Lee W, Kang JH, Kim W, Kim YJ, et al. Nonalcoholic fatty liver disease is associated with coronary artery calcification. *Hepatology*. 2012; 56:605–613. [PubMed: 22271511]
32. Adams LA, Lymp JF, St Sauver J, Sanderson SO, Lindor KD, Feldstein A, Angulo P. The natural history of nonalcoholic fatty liver disease: a population-based cohort study. *Gastroenterology*. 2005; 129:113–121. [PubMed: 16012941]
33. McPherson S, Stewart SF, Henderson E, Burt AD, Day CP. Simple non-invasive fibrosis scoring systems can reliably exclude advanced fibrosis in patients with non-alcoholic fatty liver disease. *Gut*. 2010; 59:1265–1269. [PubMed: 20801772]
34. Dowman JK, Tomlinson JW, Newsome PN. Systematic review: the diagnosis and staging of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis. *Aliment Pharmacol Ther*. 2011; 33:525–540. [PubMed: 21198708]
35. Musso G, Gambino R, Cassader M, Pagano G. Meta-analysis: natural history of non-alcoholic fatty liver disease (NAFLD) and diagnostic accuracy of non-invasive tests for liver disease severity. *Ann Med*. 2011; 43:617–649. [PubMed: 21039302]
36. Ruhl CE, Everhart JE. Gallstone disease is associated with increased mortality in the United States. *Gastroenterology*. 2011; 140:508–516. [PubMed: 21075109]
37. Everhart JE, Khare M, Hill M, Maurer KR. Prevalence and ethnic differences in gallbladder disease in the United States. *Gastroenterology*. 1999; 117:632–639. [PubMed: 10464139]
38. Teli MR, James OF, Burt AD, Bennett MK, Day CP. The natural history of nonalcoholic fatty liver: a follow-up study. *Hepatology*. 1995; 22:1714–1719. [PubMed: 7489979]

Figure 1.
Flow diagram of participants for the study

Table 1

Characteristics of Study Participants at Initial Survey *

	NAFLD (n=4,083)	No NAFLD (n=7,071)	P Value
Age (years)	45.5 ± 0.45	41.6 ± 0.44	<0.001
Gender (male, %)	50.4 ± 1.23	45.8 ± 0.81	0.010
Body mass index (kg/m ²)	29.05 ± 0.23	25.47 ± 0.11	<0.001
Waist circumference (cm)	98.35 ± 0.58	88.62 ± 0.27	<0.001
Race-ethnicity (%)			<0.001
Non-Hispanic white	75.2 ± 1.64	76.7 ± 1.32	
Non-Hispanic black	9.1 ± 0.70	11.0 ± 0.70	
Mexican American	6.7 ± 0.68	4.7 ± 0.42	
Smoking (%)			<0.001
Never	45.1 ± 1.22	46.8 ± 1.21	
Ex-smoker	30.8 ± 1.37	23.6 ± 0.86	
Current smoking	24.1 ± 1.03	29.6 ± 1.06	
Alcohol consumption (drinks/wk)	2.27 ± 0.12	2.54 ± 0.11	<0.001
Hypertension (%)	31.0 ± 1.47	15.9 ± 0.63	<0.001
Diabetes (%)	8.4 ± 0.53	2.6 ± 0.30	<0.001
History of cardiovascular disease (%)	6.4 ± 0.47	3.3 ± 0.36	<0.001
Lipid-lowering medication (%)	4.3 ± 0.48	2.4 ± 0.30	<0.001
Systolic blood pressure (mm Hg)	124.6 ± 0.42	119.2 ± 0.34	<0.001
Diastolic blood pressure (mm Hg)	76.4 ± 0.28	73.4 ± 0.22	<0.001
Total cholesterol (mg/dL)	208.8 ± 1.46	201.2 ± 0.86	<0.001
HDL cholesterol (mg/dL)	46.4 ± 0.44	51.9 ± 0.41	<0.001
Triglycerides (mg/dL)	184.0 ± 3.66	121.8 ± 2.12	<0.001
ALT (IU/L)	21.5 ± 0.59	15.4 ± 0.28	<0.001
AST (IU/L)	22.9 ± 0.26	19.8 ± 0.17	<0.001
GGT (IU/L)	34.8 ± 1.24	24.2 ± 0.41	<0.001
Albumin (g/dL)	4.18 ± 0.02	4.22 ± 0.02	<0.001
Platelet (×10 ⁹ /L)	273.7 ± 2.79	270.1 ± 2.09	<0.001
Glucose (mg/dL)	104.9 ± 1.02	94.7 ± 0.49	<0.001
HbA1c (%)	5.57 ± 0.03	5.25 ± 0.02	<0.001
Insulin (uU/mL) (n=9,798)	13.65 ± 0.37	8.41 ± 0.14	<0.001
HOMA-IR (n=9,798)	3.67 ± 0.13	2.00 ± 0.04	<0.001

Abbreviation: NAFLD, nonalcoholic fatty liver disease; HDL, high-density lipoprotein; ALT, alanine aminotransferase; AST, aspartate aminotransferase; GGT, gamma-glutamyltransferase; HOMA-IR, homeostatic model assessment of insulin resistance.

* Mean ± standard error

NAFLD was defined as ultrasonographic presence of mild-severe hepatic steatosis in the absence of any other possible cause of chronic liver disease.

The insulin, and HOMA-IR were also calculated from fasting subject only.

Table 2

Association between NAFLD and Overall and Cause-Specific Mortality

	No. of deaths	Age, Sex-adjusted		Multivariable-adjusted*	
		Hazard ratio (95% CI)	P Value	Hazard ratio (95% CI)	P Value
Mortality from all causes	1795				
No NAFLD (n=7,012)	1016	Reference		Reference	
NAFLD (n=4,081)	779	1.05 (0.93–1.19)	0.431	0.89 (0.78–1.02)	0.101
Cardiovascular disease	673				
No NAFLD	381	Reference		Reference	
NAFLD	292	1.02 (0.85–1.22)	0.854	0.75 (0.56–1.01)	0.056
Liver disease	37				
No NAFLD	18	Reference		Reference	
NAFLD	19	1.16 (0.38–3.58)	0.788	1.90 (0.57–6.35)	0.290
Malignancy	430				
No NAFLD	263	Reference		Reference	
NAFLD	167	0.93 (0.72–1.20)	0.568	0.90 (0.65–1.26)	0.542
Diabetes	258				
No NAFLD	121	Reference		Reference	
NAFLD	137	2.18 (1.49–3.19)	<0.001	0.87 (0.59–1.29)	0.488

Abbreviation: NAFLD, nonalcoholic fatty liver disease; CI, confidence interval.

* Multivariable models adjusted for age, sex, race-ethnicity, education, income, diabetes, hypertension, history of cardiovascular disease, lipid-lowering medication, smoking status, waist circumference, alcohol consumption, caffeine consumption, total cholesterol, high-density lipoprotein-cholesterol, transferrin saturation, and C-reactive protein.

NAFLD was defined as ultrasonographic presence of mild-severe hepatic steatosis in the absence of any other possible cause of chronic liver disease.

Table 3

Characteristics of Study Participants with NAFLD According to NAFLD fibrosis score in NAFLD *

	Low NAFLD fibrosis score (n=2,755)	Intermediate NAFLD fibrosis score (n=1,151)	High NAFLD fibrosis score (n=173)	P Value
Age (years)	40.7 ± 0.47	57.2 ± 0.55	61.2 ± 1.31	<0.001
Gender (male)	50.8 ± 1.58	50.2 ± 2.34	43.7 ± 6.15	0.504
Body mass index (kg/m ²)	27.78 ± 0.23	31.69 ± 0.41	36.64 ± 0.87	<0.001
Waist circumference (cm)	94.74 ± 0.57	106.35 ± 0.92	117.06 ± 1.97	<0.001
Race-ethnicity (%)				<0.001
Non-Hispanic white	73.8 ± 2.00	79.4 ± 1.87	74.5 ± 4.25	
Non-Hispanic black	8.3 ± 0.69	10.3 ± 1.08	15.4 ± 2.39	
Mexican American	7.7 ± 0.85	4.3 ± 0.46	3.5 ± 0.68	
Smoking (%)				<0.001
Never	47.1 ± 1.33	39.3 ± 2.44	44.6 ± 5.70	
Ex-smoker	26.1 ± 1.46	43.0 ± 2.47	43.0 ± 5.09	
Current smoking	26.8 ± 1.21	17.7 ± 1.78	12.4 ± 3.56	
Alcohol consumption (drinks/wk)	2.48 ± 0.13	1.79 ± 0.17	1.42 ± 0.48	<0.001
Hypertension (%)	22.6 ± 1.50	50.9 ± 2.43	64.7 ± 5.60	<0.001
Diabetes (%)	2.77 ± 0.35	18.7 ± 1.73	55.0 ± 4.98	<0.001
History of cardiovascular disease (%)	3.1 ± 0.47	13.5 ± 1.60	25.0 ± 5.95	<0.001
Lipid-lowering medication (%)	3.0 ± 0.57	7.9 ± 1.35	5.9 ± 2.48	0.006
Systolic blood pressure (mm Hg)	121.1 ± 0.49	132.9 ± 0.73	137.5 ± 1.90	<0.001
Diastolic blood pressure (mm Hg)	76.1 ± 0.35	77.3 ± 0.44	76.2 ± 1.24	<0.001
Total cholesterol (mg/dL)	206.9 ± 1.61	213.7 ± 2.08	212.9 ± 6.45	<0.001
HDL cholesterol (mg/dL)	46.7 ± 0.54	45.6 ± 0.61	46.7 ± 2.44	<0.001
Triglycerides (mg/dL)	177.2 ± 3.19	197.9 ± 10.80	227.5 ± 20.45	<0.001
ALT (IU/L)	22.8 ± 0.75	18.4 ± 0.64	17.7 ± 1.43	<0.001
AST (IU/L)	22.8 ± 0.37	22.5 ± 0.46	28.0 ± 1.92	<0.001
Total Bilirubin (mg/dL)	0.61 ± 0.01	0.58 ± 0.01	0.63 ± 0.04	<0.001
Creatinine (mg/dL)	1.06 ± 0.01	1.11 ± 0.01	1.19 ± 0.03	<0.001
GGT (IU/L)	33.8 ± 1.46	35.3 ± 1.77	53.0 ± 7.99	<0.001
Albumin (g/dL)	4.24 ± 0.02	4.05 ± 0.02	3.89 ± 0.04	<0.001
Platelet (×10 ⁹ /L)	291.0 ± 3.32	233.3 ± 2.54	201.4 ± 6.83	<0.001
Glucose (mg/dL)	104.9 ± 1.02	99.0 ± 2.26	147.4 ± 6.45	<0.001
HbA1c (%)	5.38 ± 0.03	5.96 ± 0.07	6.89 ± 0.22	<0.001
Insulin (uU/mL) (n=3,536)	12.36 ± 0.35	16.41 ± 0.68	21.24 ± 1.37	<0.001
HOMA-IR (n=3,536)	3.12 ± 0.11	4.78 ± 0.25	7.50 ± 0.80	<0.001

* Mean ± standard error

NAFLD, nonalcoholic fatty liver disease; HDL, high-density lipoprotein; ALT, alanine aminotransferase; AST, aspartate aminotransferase; GGT, gamma-glutamyltransferase; HOMA-IR, homeostatic model assessment of insulin resistance.

NAFLD was defined as ultrasonographic presence of mild-severe hepatic steatosis in the absence of any other possible cause of chronic liver disease.

NAFLD fibrosis score = $-1.675 + 0.037 \times \text{age (years)} + 0.094 \times \text{BMI (kg/m}^2\text{)} + 1.13 \times \text{impaired fasting glycemia or diabetes (yes=1, no=0)} + 0.99 \times \text{AST/ALT ratio} - 0.013 \times \text{platelet (}\times 10^9\text{/L)} - 0.66 \times \text{albumin g/dL}$.

The insulin, and HOMA-IR were also calculated from fasting subject only.

Table 4
Association between NAFLD fibrosis score and Overall and Cause-Specific Mortality among Subjects with NAFLD

	No. of deaths	Age, Sex-adjusted		Multivariable-adjusted*	
		Hazard ratio (95% CI)	P Value	Hazard ratio (95% CI)	P Value
Mortality from all causes	778				
Low NFS	290	Reference		Reference	
Intermediate NFS	389	1.30 (1.00–1.70)	0.051	1.26 (0.98–1.64)	0.076
High NFS	99	2.17 (1.40–3.36)	<0.001	1.69 (1.09–2.63)	0.020
Cardiovascular disease	291				
Low NFS	88	Reference		Reference	
Intermediate NFS	162	2.01 (1.34–3.00)	0.001	2.16 (1.41–3.29)	<0.001
High NFS	41	3.69 (2.06–6.61)	<0.001	3.46 (1.91–6.25)	<0.001
Liver disease	19				
Low NFS	9	Reference		Reference	
Intermediate NFS	9	0.41 (0.06–2.89)	0.365	0.49 (0.08–2.83)	0.415
High NFS	1	0.05 (0.00–0.72)	0.029	0.07 (0.00–1.25)	0.070
Malignancy	167				
Low NFS	69	Reference		Reference	
Intermediate NFS	80	1.14 (0.64–2.03)	0.643	1.02 (0.54–1.95)	0.940
High NFS	18	1.33 (0.59–2.95)	0.483	1.03 (0.38–2.77)	0.953
Diabetes	137				
Low NFS	35	Reference		Reference	
Intermediate NFS	78	1.60 (0.84–3.02)	0.147	1.21 (0.52–2.84)	0.652
High NFS	24	4.46 (2.00–9.97)	<0.001	1.65 (0.50–5.41)	0.402

Abbreviation: NAFLD, nonalcoholic fatty liver disease; CI, confidence interval; NFS, NAFLD fibrosis score.

* Multivariable models adjusted for age, sex, race-ethnicity, education, income, diabetes, hypertension, history of cardiovascular disease, lipid-lowering medication, smoking status, waist circumference, alcohol consumption, caffeine consumption, total cholesterol, high-density lipoprotein-cholesterol, transferrin saturation, and C-reactive protein.

NAFLD was defined as ultrasonographic presence of mild-severe hepatic steatosis in the absence of any other possible cause of chronic liver disease.

NAFLD fibrosis score = $-1.675 + 0.037 \times \text{age (years)} + 0.094 \times \text{BMI (kg/m}^2\text{)} + 1.13 \times \text{impaired fasting glycemia or diabetes (yes=1, no=0)}$
 $\text{AST/ALT ratio} - 0.013 \times \text{platelet } (\times 10^9/\text{L}) - 0.66 \times \text{albumin g/dL}$.

Because of smaller numbers of deaths, education, income, history of cardiovascular disease, lipid-lowering medication and C-reactive protein were excluded from model for liver disease.

Table 5
Association between APRI and FIB-4 score and Overall and Cause-Specific Mortality among Subjects with NAFLD

	APRI*		FIB-4*	
	Hazard ratio (95% CI)	P Value	Hazard ratio (95% CI)	P Value
Mortality from all causes				
Low score	Reference		Reference	
Intermediate score	1.32 (0.78–2.23)	0.294	1.46 (1.16–1.82)	0.002
High score	1.85 (1.02–3.37)	0.044	1.66 (0.98–2.82)	0.060
Cardiovascular disease				
Low score	Reference		Reference	
Intermediate score	0.97 (0.40–2.34)	0.937	1.75 (1.26–2.43)	0.001
High score	2.53 (1.33–4.83)	0.006	2.68 (1.44–4.99)	0.003
Liver disease				
Low score	Reference		Reference	
Intermediate score	6.08 (0.77–48.21)	0.086	0.68 (0.11–4.05)	0.667
High score	3.01 (0.20–45.62)	0.420	1.32 (0.12–14.80)	0.821
Malignancy				
Low score	Reference		Reference	
Intermediate score	2.33 (0.91–5.96)	0.076	0.89 (0.49–1.63)	0.705
High score	2.31 (0.35–15.10)	0.374	0.96 (0.19–4.82)	0.962
Diabetes				
Low score	Reference		Reference	
Intermediate score	0.41 (0.12–1.46)	0.166	0.98 (0.57–1.68)	0.945
High score	29.36 (10.05–85.74)	<0.001	2.89 (0.33–25.35)	0.330

Abbreviation: NAFLD, nonalcoholic fatty liver disease; CI, confidence interval; APRI, the aspartate transaminase to platelet ratio index.

* Models adjusted for age, sex, race-ethnicity, education, income, diabetes, hypertension, history of cardiovascular disease, lipid-lowering medication, smoking status, waist circumference, alcohol consumption, caffeine consumption, total cholesterol, high-density lipoprotein-cholesterol, transferrin saturation, and C-reactive protein.

$$\text{APRI} = \left(\frac{\text{AST}}{\text{upper limit of normal}} \right) / \left(\frac{\text{platelet count}}{10^9 / \text{L}} \right) \times 100$$
$$\text{FIB-4} = (\text{Age [years]} \times \text{AST [U/L]} / (\text{platelet} [10^9 / \text{L}] \times (\text{ALT [U/L]})^{1/2})$$

Because of smaller numbers of deaths, education, income, history of cardiovascular disease, lipid-lowering medication and C-reactive protein were excluded from model for liver disease.